Published April 20, 2022 | Version v1
Journal article Open

The effect of the galectin-3 inhibitor GB0139 on acute lung injury

Creators

  • 1. Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
  • 2. Galecto Inc, Copenhagen, Denmark
  • 3. Galecto Inc. Stevenage Bioscience Catalyst, Stevenage, UK
  • 4. Department of Laboratory Medicine, Lund University, Lund, Sweden
  • 5. Department of Chemistry, Lund University, Lund, Sweden
  • 6. Department of Asthma, Allergy and Respiratory Science, King's College London, Guy's Hospital, London, UK
  • 7. Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK; Galecto Inc, Edinburgh Bioquarter, Edinburgh, UK.

Description

This study investigates the impact of Galectin-3 and the Galectin-3 inhibitor, GB0139, in acute lung injury models in mice, and on neutrophil and epithelial cell activation in vitro.

Files

Files (11.2 MB)